Ana Mellado Fuentes

Ana Mellado Fuentes

Auto-generated profile, based on publicly available information

Ana Mellado Fuentes

BioMed X GmbH, Im Neuenheimer Feld 515, 69120 Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2024 in Science Advances
Verified
Journal Article
Open access
MCMiray Cetin
Miray Cetin
VPVeronica Pinamonti
Veronica Pinamonti
TSTheresa Schmid
Theresa Schmid
TBTamara Boschert
Tamara Boschert
AFAna Mellado Fuentes
Ana Mellado Fuentes
JLJohn M. Lindner
John M. Lindner
Effective, unbiased, high-throughput methods to functionally identify both class II and class I HLA–presented T cell epitopes and their cognate T cell receptors (TCRs) are essential for and prerequisite to diagnostic and therapeutic applications, yet remain underdeveloped. Here, we present T-FINDER [T cell Functional Identification and (Neo)-antigen Discovery of Epitopes and Receptors], a system to rapidly deconvolute CD4 and CD8 TCRs and targets physiologically processed and presented by an individual’s unmanipulated, complete human leukocyte antigen (HLA) haplotype. Combining a highly sensitive TCR signaling reporter with an antigen processing system to overcome previously undescribed limitations to target expression, T-FINDER both robustly identifies unknown peptide:HLA ligands from antigen libraries and rapidly screens and functionally validates the specificity of large TCR libraries against known or predicted targets. To demonstrate its capabilities, we apply the platform to multiple TCR-based applications, including diffuse midline glioma, celiac disease, and rheumatoid arthritis, providing unique biological insights and showcasing T-FINDER’s potency and versatility.